SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKIGlobeNewsWire · 2 days ago
ICU Medical Announces Time of Third Quarter 2026 Earnings Conference CallGlobeNewsWire · 3 days ago
SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology AwardGlobeNewsWire · Oct 14, 2026
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic ConditionGlobeNewsWire · Oct 7, 2026
SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross ProceedsGlobeNewsWire · Oct 5, 2026
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026GlobeNewsWire · Oct 2, 2026SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.97 | -$0.91 | Beat |
| May 13, 2026 | -$0.73 | -$0.90 | Miss |
| Mar 25, 2026 | -$0.97 | -$0.80 | Beat |
| Nov 13, 2025 | -$1.50 | -$1.30 | Beat |
| Aug 13, 2025 | -$4.30 | -$1.80 | Beat |
| May 14, 2025 | -$5.20 | -$4.40 | Beat |